Janusz Hałka
Research Subjects
Research Interests
Janusz Hałka has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Giza
Department of Haematology, Jagiellonian University Medical College, 30-688 Krakow, Poland
1 shared publication - Anna Morawska-Krekora
Department of Hematology and Internal Diseases, Ludwik Rydygier’s Hospital, 31-820 Krakow, Poland
1 shared publication - Damian Mikulski
Department of Hemato-Oncology and Internal Medicine, Copernicus Memorial Hospital
1 shared publication - Dariusz Wołowiec
Department of Hematology, Cellular Therapies and Internal Diseases, Wrocław Medical University, 50-567 Wrocław, Poland
1 shared publication - Ewa Paszkiewicz-Kozik
Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
1 shared publication - Joanna Drozd-Sokołowska
Central Clinical Hospital, The Medical University of Warsaw, Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 21 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 548
Primary Renal Lymphoma: Report of 32 Cases—A Retrospective Multicenter PLRG Analysis
Introduction: Primary renal lymphoma is extremely rare, accounting for less than 1% of all lymphomas. Objectives: The aim of this study was to describe a group of patients with primary renal lymphoma diagnosed in hematology and oncology centers aligned with the Polish Lymphoma Research Group (PLRG). Patients and methods: This was a retrospective analysis of adult patients with primary renal lymphoma diagnosed at PLRG centers. Results: Thirty-two patients were diagnosed in seven centers over 24 years (2000–2023). The most common type of lymphoma was diffuse large B-cell lymphoma (DLBCL). The median progression-free survival (PFS) after first-line treatment was 2.1 (95% CI: 1.07–4.18) years, while the median overall survival (OS) was 6.3 (95% CI: 1.82–6.34) years. The median age at diagnosis was 63.3 years old, and 59.4% of the patients were females. In multivariate Cox regression for PFS, only creatinine > 1.5 mg/dL (HR 10.2, 95% CI: 2.08–50.09, p = 0.004) and hemoglobin (Hgb) < 10 g/dL (HR 8.39, 95% CI: 1.88–37.49) were associated with inferior PFS. Patients who achieved complete remission (CR) after first-line of treatment had significantly longer PFS (median 4.18, 95% CI: 2.02–4.18 vs. median 0.73, 95% CI: 0.50–0.79, p = 0.004) and OS (median not reached vs. median 1.49, 95% CI: 0.43–6.33, p = 0.001). Patients treated with nephrectomy had longer OS (median not reached vs. median 5.07, 95% CI: 1.32–5.08, p = 0.05). However, in multivariate Cox regression for OS, only hypoalbuminemia was an independent factor for inferior survival (HR 5.44, 95% CI: 1.12–26.38, p = 0.04). Conclusions: Primary renal lymphoma is an extremely rare type of lymphoma with a poor prognosis. The prognosis may improve with future advances in treatment, including nephrectomy.
- 21 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 548
Open AccessPrimary Renal Lymphoma: Report of 32 Cases—A Retrospective Multicenter PLRG Analysis
Introduction: Primary renal lymphoma is extremely rare, accounting for less than 1% of all lymphomas. Objectives: The aim of this study was to describe a group of patients with primary renal lymphoma diagnosed in hematology and oncology centers aligned with the Polish Lymphoma Research Group (PLRG). Patients and methods: This was a retrospective analysis of adult patients with primary renal lymphoma diagnosed at PLRG centers. Results: Thirty-two patients were diagnosed in seven centers over 24 years (2000–2023). The most common type of lymphoma was diffuse large B-cell lymphoma (DLBCL). The median progression-free survival (PFS) after first-line treatment was 2.1 (95% CI: 1.07–4.18) years, while the median overall survival (OS) was 6.3 (95% CI: 1.82–6.34) years. The median age at diagnosis was 63.3 years old, and 59.4% of the patients were females. In multivariate Cox regression for PFS, only creatinine > 1.5 mg/dL (HR 10.2, 95% CI: 2.08–50.09, p = 0.004) and hemoglobin (Hgb) < 10 g/dL (HR 8.39, 95% CI: 1.88–37.49) were associated with inferior PFS. Patients who achieved complete remission (CR) after first-line of treatment had significantly longer PFS (median 4.18, 95% CI: 2.02–4.18 vs. median 0.73, 95% CI: 0.50–0.79, p = 0.004) and OS (median not reached vs. median 1.49, 95% CI: 0.43–6.33, p = 0.001). Patients treated with nephrectomy had longer OS (median not reached vs. median 5.07, 95% CI: 1.32–5.08, p = 0.05). However, in multivariate Cox regression for OS, only hypoalbuminemia was an independent factor for inferior survival (HR 5.44, 95% CI: 1.12–26.38, p = 0.04). Conclusions: Primary renal lymphoma is an extremely rare type of lymphoma with a poor prognosis. The prognosis may improve with future advances in treatment, including nephrectomy.